Trial Profile
Apatinib mesylate tablets combined with docetaxel and nedaplatin in the treatment of advanced ovarian cancer by observational clinical study of postoperative patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel; Nedaplatin
- Indications Ovarian cancer
- Focus Therapeutic Use
- 14 Jul 2017 New trial record